[go: up one dir, main page]

NO20033418L - Immunregulatoriske antistoffer og anvendelse derav - Google Patents

Immunregulatoriske antistoffer og anvendelse derav

Info

Publication number
NO20033418L
NO20033418L NO20033418A NO20033418A NO20033418L NO 20033418 L NO20033418 L NO 20033418L NO 20033418 A NO20033418 A NO 20033418A NO 20033418 A NO20033418 A NO 20033418A NO 20033418 L NO20033418 L NO 20033418L
Authority
NO
Norway
Prior art keywords
immune regulatory
regulatory antibodies
antibodies
immune
regulatory
Prior art date
Application number
NO20033418A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033418D0 (no
Inventor
Kandasamy Hariharan
Nabil Hanna
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/772,938 external-priority patent/US20020006404A1/en
Priority claimed from US09/855,717 external-priority patent/US20020028178A1/en
Priority claimed from US09/985,646 external-priority patent/US20020159996A1/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of NO20033418D0 publication Critical patent/NO20033418D0/no
Publication of NO20033418L publication Critical patent/NO20033418L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20033418A 2001-01-31 2003-07-30 Immunregulatoriske antistoffer og anvendelse derav NO20033418L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/772,938 US20020006404A1 (en) 1999-11-08 2001-01-31 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US09/855,717 US20020028178A1 (en) 2000-07-12 2001-05-16 Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US09/985,646 US20020159996A1 (en) 2001-01-31 2001-11-05 Use of CD23 antagonists for the treatment of neoplastic disorders
US33118701P 2001-11-09 2001-11-09
PCT/US2002/002621 WO2002060485A2 (fr) 2001-01-31 2002-01-31 Anticorps immunoregulateurs et ses utilisations

Publications (2)

Publication Number Publication Date
NO20033418D0 NO20033418D0 (no) 2003-07-30
NO20033418L true NO20033418L (no) 2003-09-30

Family

ID=27502437

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033418A NO20033418L (no) 2001-01-31 2003-07-30 Immunregulatoriske antistoffer og anvendelse derav

Country Status (8)

Country Link
US (1) US20070009519A1 (fr)
EP (1) EP1372724A2 (fr)
JP (1) JP4463475B2 (fr)
CN (1) CN100574803C (fr)
AU (1) AU2002243718B2 (fr)
CA (1) CA2436180C (fr)
NO (1) NO20033418L (fr)
WO (1) WO2002060485A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
ES2538469T3 (es) 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP2301575A1 (fr) * 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Procédé de thérapie pour tumeurs solides exprimant l'antigène de la surface de cellule CD40
ME01775B (fr) * 2003-11-05 2011-02-28 Glycart Biotechnology Ag Molecules fixatrices d'antigenes presentant une affinite de fixation du recepteur de fc et une fonction effectrice accrues
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
WO2007014278A2 (fr) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
US8926979B2 (en) 2005-11-01 2015-01-06 Novartis Ag Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
US20110105724A1 (en) * 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
CN101199862B (zh) * 2007-12-19 2011-07-06 北京大学第三医院 B7-1、cd40l质粒混合物
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PL2544719T3 (pl) * 2010-03-12 2020-01-31 Debiopharm International S.A. Cząsteczki wiążące cd37 i ich immunokoniugaty
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
MX2013011385A (es) 2011-04-01 2014-03-13 Immunogen Inc Moleculas de union a cd37 y sus inmunoconjugados.
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US9321833B2 (en) 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
TWI739740B (zh) 2015-04-22 2021-09-21 德商奎爾法克股份有限公司 用於治療腫瘤疾病之含有ｒｎａ的組成物
WO2016200676A1 (fr) 2015-06-08 2016-12-15 Immunogen, Inc. Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
JP6890581B2 (ja) 2015-08-28 2021-06-18 デビオファーム インターナショナル， エス． アー． Ｃｄ３７の検出のための抗体およびアッセイ
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc The CD45–GATE vehicle activates a protease
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
CN116790594A (zh) 2022-06-30 2023-09-22 北京键凯科技股份有限公司 一种抑制b7-h3基因表达的干扰rna及其应用
CN119654406A (zh) 2022-07-29 2025-03-18 艾洛基治疗公司 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞
WO2025096560A1 (fr) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cellules modifiées

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
EP0669836B1 (fr) 1992-11-13 1996-07-03 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU686230B2 (en) 1993-10-01 1998-02-05 Immunex Corporation Antibodies to CD40
US5874085A (en) 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
ES2222463T3 (es) 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US5667165A (en) 1994-08-01 1997-09-16 Gardner; Gregory P. Apparatus and method for application of flexible sheet stock
EP0771208B1 (fr) 1994-08-12 2005-10-19 Immunomedics, Inc. Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
DE4434989A1 (de) 1994-09-30 1996-04-04 Basf Ag Reaktive Azofarbstoffe mit einer Kupplungskomponente aus der Aminonaphthalinreihe
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
BR9713498A (pt) * 1996-11-08 2000-02-29 Idec Pharma Corp Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
EP1009432A4 (fr) * 1997-06-11 2004-07-07 Us Navy Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
US6897044B1 (en) * 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
IL144559A0 (en) * 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
WO2000074634A2 (fr) * 1999-06-03 2000-12-14 Au Jessie L S Methodes et compositions permettant de moduler la proliferation et la mort cellulaire
JP2003513937A (ja) * 1999-11-08 2003-04-15 アイデック・ファーマシューティカルズ・コーポレイション 抗ｃｄ２０抗体および／または化学療法薬および放射線療法と併用して抗ｃｄ４０ｌ抗体を使用するｂ細胞悪性疾患の処置
CA2404365A1 (fr) * 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
CA2399940A1 (fr) * 2000-04-13 2001-10-25 The Rockefeller University Amelioration des reponses immunitaires associees aux anticorps
AU2001264747A1 (en) * 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
EP1305045A1 (fr) * 2000-07-12 2003-05-02 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
US20070009519A1 (en) 2007-01-11
JP4463475B2 (ja) 2010-05-19
CN100574803C (zh) 2009-12-30
CA2436180C (fr) 2011-11-08
WO2002060485A2 (fr) 2002-08-08
WO2002060485A3 (fr) 2003-06-05
NO20033418D0 (no) 2003-07-30
AU2002243718B2 (en) 2007-12-06
JP2005503326A (ja) 2005-02-03
CN1568198A (zh) 2005-01-19
EP1372724A2 (fr) 2004-01-02
WO2002060485A9 (fr) 2004-04-01
CA2436180A1 (fr) 2002-08-08

Similar Documents

Publication Publication Date Title
NO20033418D0 (no) Immunregulatoriske antistoffer og anvendelse derav
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1746375T3 (da) Oxygendrevet forbrændingssystem og anvendelser deraf
NO20033456D0 (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
DE60220542D1 (de) Fördereinrichtung
DK1228217T3 (da) Konserverede neisseria-antigener
EP1412378A4 (fr) Aptameres et antiaptameres
DK1423376T3 (da) Bicyklisk forbindelse, fremstilling og anvendelse deraf
DK1309692T3 (da) Anti-IL12-antistoffer, præparater, fremgangsmåder og anvendelser
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20032542L (no) Dempede anti-CD28-antistoffer og anvendelse derav
DE60220486D1 (de) Zurückschaltungseinrichtung und Zurückschaltungsverfahren
EE200300569A (et) CD44v6-spetsiifilised antikehad
FI20012087A0 (fi) Hihnakuljetin ja puhdistinlaite
NO20022626D0 (no) Reagenser og komplekser